Equities

Nautilus Biotechnology Inc

NAUT:NSQ

Nautilus Biotechnology Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.49
  • Today's Change0.07 / 2.89%
  • Shares traded159.70k
  • 1 Year change-6.04%
  • Beta1.0023
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

  • Revenue in USD (TTM)0.00
  • Net income in USD-70.21m
  • Incorporated2016
  • Employees161.00
  • Location
    Nautilus Biotechnology Inc2701 Eastlake Ave EastSEATTLE 98102United StatesUSA
  • Phone+1 (206) 333-2001
  • Fax+1 (302) 655-5049
  • Websitehttps://www.nautilus.bio/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
aTyr Pharma Inc235.00k-63.82m282.05m56.00--3.90--1,200.20-0.9365-0.93650.00340.86170.0022--0.124,196.43-58.90-45.45-67.15-52.74-----27,155.32-784.19----0.0233---96.60---11.14--47.98--
Atea Pharmaceuticals Inc0.00-174.01m283.66m75.00--0.6189-----2.07-2.070.005.430.00----0.00-31.67-5.90-32.99-6.98-------38.91----0.00-------17.30------
Zentalis Pharmaceuticals Inc40.56m-194.65m286.57m168.00--0.749--7.07-2.75-2.750.57195.380.0729--15.94241,428.60-34.99-47.40-39.16-54.18-----480.07------0.00-------23.39--20.76--
ADC Therapeutics SA70.72m-212.15m288.14m273.00------4.07-2.40-2.400.7742-1.780.17330.29873.13259,036.60-51.13-48.41-62.27-55.6391.81---295.00-308.624.68-3.921.65---66.86127.56-52.78--5.42--
Biomea Fusion Inc0.00-144.01m291.00m107.00--3.83-----4.00-4.000.002.100.00----0.00-85.85---98.73--------------0.00-------43.29------
Fate Therapeutics Inc12.32m-175.72m291.53m181.00--0.7342--23.67-1.71-1.710.11853.490.0221--6.3568,049.73-31.56-31.82-33.99-36.05-----1,426.67-359.33----0.00---34.0368.0542.88--21.72--
Zura Bio Ltd0.00-42.62m301.01m14.00--2.01-----0.5807-0.58070.002.340.00----0.00-32.18---43.31--------------0.00-------2,050.99------
Tscan Therapeutics Inc12.20m-104.41m301.95m175.00--1.18--24.75-1.05-1.050.12254.820.0353----79,220.78-30.19---33.78-------855.84------0.1066--55.52---34.73------
Nautilus Biotechnology Inc0.00-70.21m303.86m161.00--1.36-----0.561-0.5610.001.780.00----0.00-24.29---25.05--------------0.00-------9.93------
Ocugen Inc8.19m-45.87m308.01m65.00--16.27--37.60-0.1785-0.17850.03190.06580.1265----126,015.40-78.54-83.56-103.70-97.79-----620.91-2,921.94----0.1445--142.60--27.33--39.08--
Mersana Therapeutics Inc29.94m-104.77m310.37m123.00--36.83--10.37-0.8648-0.86480.24690.06870.1222--38.14243,390.30-42.75-61.68-59.36-81.35-----349.98-622.19----0.7508--38.6528.3215.94--9.61--
Vanda Pharmaceuticals Inc.190.86m-16.39m311.27m203.00--0.5753--1.63-0.2824-0.28243.299.280.29679.305.30940,187.20-2.556.61-2.957.6293.6290.55-8.5915.184.84--0.000.00-24.27-0.0496-60.02-36.96-56.77--
AC Immune SA17.59m-68.72m313.64m133.00--2.24--17.83-0.7289-0.72890.191.410.0787--28.76132,255.70-30.73-18.25-42.90-19.52-----390.68-148.29---128.010.0255--276.1415.5223.35---15.49--
AVITA Medical Inc60.04m-57.32m317.07m207.00--26.16--5.28-2.23-2.232.330.46640.74091.537.30290,048.30-70.74---86.14--86.46---95.47--3.37-11.270.7768--45.68---32.69------
Artiva Biotherapeutics Inc-100.00bn-100.00bn324.96m82.00--------------1.09----------------------------0.0087--579.21--51.15------
Data as of Nov 12 2024. Currency figures normalised to Nautilus Biotechnology Inc's reporting currency: US Dollar USD

Institutional shareholders

25.37%Per cent of shares held by top holders
HolderShares% Held
Perceptive Advisors LLCas of 30 Jun 202412.59m10.04%
Cercano Management LLCas of 30 Jun 20247.17m5.72%
BlackRock Fund Advisorsas of 30 Jun 20243.11m2.48%
The Vanguard Group, Inc.as of 30 Jun 20242.68m2.14%
Comprehensive Financial Management LLC (California)as of 30 Jun 20242.21m1.76%
Geode Capital Management LLCas of 30 Jun 20241.13m0.91%
SSgA Funds Management, Inc.as of 30 Jun 2024941.24k0.75%
Tikvah Management LLCas of 30 Jun 2024726.90k0.58%
The Clarius Group LLCas of 30 Sep 2024636.53k0.51%
Botty Investors LLCas of 30 Jun 2024614.27k0.49%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.